Colorectal Cancer

Last updated: November 27, 2025
Table Of Contents

Colorectal cancer

Colorectal cancer is the third most common cancer and the second most common cause of death from cancer. The incidence is increasing in Sub-Saharan Africa and in younger patients. Rectal cancer is as common as colon cancer. Screening for colorectal cancer is offered every 2 years to all men and women aged 50 – 74 years, beginning with a FOBT, then a colonoscopy.

80% of colorectal cancers are sporadic.

Syndromes associated with hereditary colorectal cancer

SyndromeDescription
Familial adenomatous polyposis (FAP, 1%)Autosomal dominant condition caused by mutation in the APC gene. Characterized by hundreds to thousands of adenomatous polyps in the colon which begin to develop shortly after puberty. 100% of patients with FAP develop colorectal cancer by 50 years old. Total proctocolectomy is the treatment once polyps begin to develop
Attenuated FAPPolyps appear later in life and cancer develops in about 50% of patients in middle age.
Hereditary non-polyposis colon cancer (1-3%, HNPCC /Lynch Syndrome)Autosomal dominant condition caused by mutation of DNA mismatch repair genes (MLH1 or MSH2). 70% of individuals develop colon cancer, commonly right-sided. Diagnosis is made using the Amsterdam criteria.
Familial colorectal cancer (10-15%)A family history of colon cancer carries a 12% risk of developing colon cancer with one first-degree relative and 35% with two or more (6% in patients without a family history).
Juvenile polyposis syndrome (JPS)Autosomal dominant syndrome characterized by multiple harmatomatous polyps throughout the gastrointestinal tract. Has an increased risk of colorectal and gastric cancer. 30-50% of patients develop colon cancer by 45 years.

Duke’s staging of colorectal cancer

Duke stageDescription
AInvasion not breaching the muscularis propria i.e. tumor confined to mucosa and submucosa
BLocal invasion breaching the muscularis propria but no regional lymph node involvement
CRegional lymph node metastases
DDistant metastases
  • Risk factors for colon cancer
    • Older age (90% occur above 50 years old)
    • High fat diet
    • Low-fiber diet (high fiber diet is protective)
    • Long-standing inflammatory bowel disease (both Crohn’s and ulcerative colitis)
    • Hereditary colorectal cancer syndromes
    • Alcohol and smoking
    • Obesity
  • Pathophysiology
    • Colon cancers arise through the adenoma-carcinoma sequence
    • APC/B-catenin pathway (80%): activated in the classic adenoma carcinoma sequence. Loss of APC function causes b-catenin to accumulate and activate transcription (MYC, Cyclin D1). Also associated with mutation in KRAS, SMAD2, SMAD4, TP53, methylation of CpG islands (silencing of tumor suppressor genes), and increased telomerase expression
    • Microsatellite instability (MSI) pathway: associated with defects in mismatch repair and accumulation of mutations in microsatellite repeat regions of the genome. Genes involve include MLH1, MSH2, MSH6, PMS1, PMS2. Common in sessile serrated lesions and frequently causes right-sided cancer
    • Both pathways involve multiple genetic alterations occuring over a period of time, which resultin in an invasive tumor.
  • Patient history
    • Older age
    • Family history of colon cancer
    • Inflammatory bowel disease
    • High-fat diet
    • Familial polyp disease
  • Signs and symptoms
    • Asymptomatic until advanced stages
    • Rectal bleeding
      • Melaena
      • Hematochezia
      • Maroon coloured stool
    • Change in bowel habits
      • Diarrhoea (common with right sided lesions)
      1. Constipation
      2. Tenesmus
    • Obstruction
    • Right-sided lesions commonly present with anaemia and melaena
    • Left-sided regions are more likely to present with hematochezia and obstruct (left colon is smaller in caliber and has a firmer stool consistency)
    • Fatigue
    • Anorexia
  • Investigations
    • Fecal occult blood testing (FOBT): has a positive predictive value (PPV) of 5 – 15%. The PPV for an adenoma is 30 – 45%.
    • Colonoscopy with biopsy: best initial test for patients with an abnormal fecal occult blood testing. Screening reduces mortality by 16%.
      • 5 out of 10 patients have anormal exam
      • 4 out of 10 patients have polyps that may be removed due to their premalignant potential
      • 1 out of 10 patients has cancer
  • Treatment
    • Resection
    • Chemotherapy

Location of cancer and procedure

LocationProcedure
Right sided colonRight colectomy with ligation of the ileocolic artery
Transverse colonTransverse colectomy with ligation of the IMA
Descending colonLeft colectomy with ligation of the IMA
Sigmoid colonLeft colectomy with ligation of IMA
Rectum > 3 cm from the dentate lineLow anterior resection (LAR)
Rectum < 3 cm from the dentate lineAbdominoperineal resection (APR)
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *